Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Hematopoietic Stem Cell Transplant (HSCT): early-phase trial registry

3 of 4 indexed Hematopoietic Stem Cell Transplant (HSCT) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Hematopoietic Stem Cell Transplant (HSCT): 4 US clinical trials tracked, 3 recruiting.

Hematopoietic Stem Cell Transplant (HSCT) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Hospital Medical Center, Cincinnati, running 2 of these trials.

Enrollment posture brief

Registry condition hematopoietic-stem-cell-transplant-hsct

OPEN 3 | RECR 75% | LATE 0 | EARLY 3 | RANK #4115 | SPON 2

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Hematopoietic Stem Cell (th…75%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Hematopoietic Stem Cell Transplant (HSCT)

Hematopoietic Stem Cell Transplant (HSCT) lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hematopoietic Stem Cell Transplant (HSCT) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hematopoietic Stem Cell Transplant (HSCT) is recruiting above its size-band peers.

    3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 23

Phase Distribution

PhaseTrial count
Phase 2 3

Named interventions

Most-linked intervention names on Hematopoietic Stem Cell Transplant (HSCT) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
PUL-042 Drug
1 trials
Ivosidenib Drug
1 trials
Ruxolitinib Drug
1 trials

US sites by state

Facility locations filed on Hematopoietic Stem Cell Transplant (HSCT) trials. A trial with sites in several states counts in each.

Minnesota 3 trials
Massachusetts 3 trials
Washington 2 trials
Texas 2 trials
Ohio 2 trials
California 2 trials
Wisconsin 1 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hematopoietic Stem Cell Transplant (HSCT) page

4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematopoietic Stem Cell Transplant (HSCT) condition card totals 4 registered trials; most-linked intervention Placebo; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.